HARRISON.AI

AI Focus Areas

• Medical imaging diagnostics (CT, X-ray, MRI)
• Radiology foundation models and vision–language models
• Stroke, lung disease, and oncology detection
• Clinical workflow and triage optimization
• Regulated, clinically validated AI devices

Key Products

• Harrison.ai Comprehensive Care imaging suite
• Annalise CXR and head CT solutions
• Franklin.ai pathology platform
• Navigator Pro and Rapid Enterprise-style workflow tools

Market Position

Harrison.ai is one of the most advanced independent medical imaging AI companies, with solutions deployed at over 1,000 sites across 40+ countries and more than 3,500 clinicians using its tools. Its radiology AI has underpinned key clinical trials that expanded stroke and imaging guidelines, and it now covers a broad set of chest X-ray and neuroimaging findings. The company differentiates through clinician-led development, extensive clinical validation (including multiple FDA clearances and a Breakthrough Device), and integration into existing radiology workflows. Competing with players like Viz.ai and Aidoc, Harrison.ai emphasizes end-to-end diagnostic support and workflow automation rather than just triage or notification.

AGI Relevance

Medical imaging is a complex reasoning domain that demands reliability, interpretability, and alignment with clinical standards—qualities central to safe AGI. Harrison.ai’s work on vision-language models for radiology, radiologist-in-the-loop training, and structured reporting provides blueprints for how future AGI systems might safely augment or even perform aspects of expert decision-making. Their deployment at scale in national health systems (e.g., NHS and Hong Kong public hospitals) shows how governance, validation, and monitoring frameworks can keep AI within acceptable safety envelopes. Lessons from their path to regulatory clearance and reimbursement will likely inform broader frameworks for high-stakes AGI deployment in healthcare and beyond.

Investment Highlights

Harrison.ai has raised more than US$240M, including a ~US$92M Series B in 2021 and a US$112M Series C in February 2025 co-led by Aware Super, ECP, and Horizons Ventures, with participation from Australia’s National Reconstruction Fund and existing investors like Blackbird Ventures and Alpha JWC Ventures. The company has also attracted government-backed funding via the National Reconstruction Fund’s stake.

Tags

• Medical AI
• Healthcare
• Radiology